Skip to content
Screener

Zymeworks ZYME Milestone revenue — Research and development collaborations

Other product segments

Other drug supply
$1.66M—
Royalties
$1.59M—
Drug supply for ongoing studies
$791K—
Development support payments
$291K—
Option exercise fee
$0—
Recognition of deferred revenue
$0—

Similar metrics at other companies

BioCryst Pharmaceuticals logo
BCRXResearch and Development — Collaboration revenue
$1.22M—
Kopin logo
KOPNResearch And Development Revenues — Revenue
$1.29M+4.3%
Kopin logo
KOPNResearch And Development — Revenue
$1.29M+4.3%
SIGA Technologies logo
SIGAResearch And Development — Revenue
$3.13M+57.0%
Ionis Pharmaceuticals logo
IONSResearch And Development Revenue — Revenue
$149.33M-57.2%
Denali Therapeutics Inc. logo
DNLIMilestone Payment — Total collaboration revenue
$2.5M0.0%

Other financials

Income statement

See full
Revenue$4.6M-90.6%
Operating income-$42.2M-6,158%
Net income-$45.0M-2,043%
EPS (diluted)-$0.62-2,167%

Balance sheet

See full
Cash & equivalents$179.4M+82.6%
Total debt$16.0M-14.3%
Total equity$80.4M-76.0%
Total assets$397.0M-2.8%

Cash flow

See full
Operating cash flow-$31.9M-365%
CapEx$216.0K+1,250%
Free cash flow-$31.9M-376%

Valuation

See full
Market cap$1.7B+83.2%
Enterprise value$1.54B+81.1%
P/S45.8×+38.3×

Profitability

See full
Operating margin-419%-518pp
Net margin-404%-489pp
FCF margin-324.7%-366pp

Returns & leverage

See full
Return on equity-72.3%-117pp
Debt / equity0.2×+0.1×
Current ratio6.3×-1.4×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Zymeworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001937653-26-000047
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other drug supply45—1622,150
Royalties1,5895502,919752
BeOne:
Milestone revenue—20,000—20,000
Recognition of deferred revenue—18,334—18,334
Drug supply1,66471,664215
Royalties2101943419
Bristol-Myers Squibb company, (“BMS”):

Item 1. Financial Statements

FAQ

What is Zymeworks's milestone revenue — research and development collaborations?
Zymeworks (ZYME) reported milestone revenue — research and development collaborations of $0 in Q2 2026.
How has Zymeworks's milestone revenue — research and development collaborations changed year-over-year?
Zymeworks's milestone revenue — research and development collaborations decreased by 100.0% year-over-year, from $20M to $0.
What does milestone revenue — research and development collaborations mean?
This metric represents revenue recognized from research and development collaboration agreements upon the achievement of specific clinical, regulatory, or commercial milestones. It reflects the successful progression of partnered therapeutic programs and the realization of contingent payments defined within strategic biopharmaceutical alliances. This revenue stream is a key indicator of the company's ability to validate its technology platforms through external partnerships.

Ask your AI about Zymeworks's milestone revenue — research and development collaborations.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude